-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-506546-23-00
5
2020-05-20
Acute myeloid leukemia
-
2023-509699-41-00
9
2019-11-22
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
-
2023-507883-38-00
5
2019-11-18
Systemic Juvenile Idiopathic Arthritis
-
2023-503433-21-00
5
2019-10-03
Behçet’s disease is a chronic, relapsing, multisystem inflammatory dis
-
2023-508455-38-00
5
2019-09-12
Hyperkalaemia
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-512701-11-00
4
2018-08-29
Systemic Juvenile Idiopathic Arthritis (sJIA)
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2023-504520-26-00
5
2017-10-19
Duchenne Muscular Dystrophy (DMD)
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2023-506180-34-01
7
2026-04-10
Ornithine Transcarbamylase Deficiency (OTC)
-
2023-503684-42-00
4
2026-02-20
Neuroblastoma
-
2024-515438-33-00
5
2026-01-12
Alopecia areata
-
2023-508988-73-00
5
2025-10-29
Cytomegalovirus (CMV) infection in children and adolescents who have r
-
2024-520109-37-00
4
2025-07-09
PMM2-CDG
-
2024-518519-20-01
4
2025-04-10
moderate/severe allergic rhinitis/rhinoconjunctivitis with/without con
-
2023-508510-42-00
5
2025-03-24
DUCHENNE MUSCULAR DYSTROPHY (DMD)
-
2024-511287-85-00
5
2025-02-17
Cholestatic Pruritus